Last reviewed · How we verify

NCT04349995: PFO PMS Jpn

Amplatzer PFO Occluder Post-marketing Surveillance Study

Active, enrolled Last updated 1 November 2024
What this trial tests

trial testing Amplatzer PFO Occluder in PFO - Patent Foramen Ovale in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 October 2019
Primary endpoint
14 December 2022
28 May 2026

Quick facts

Lead sponsorAbbott Medical Devices
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment500
Start date1 October 2019
Primary completion14 December 2022
Estimated completion28 May 2026
Sites1 location across Japan

Drugs / interventions tested

Conditions studied

Sponsor

Abbott Medical Devices — full company profile →

Who can join

Eligibility, any sex, with PFO - Patent Foramen Ovale. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the Amplatzer PFO Occluder post-marketing clinical use surveillance study is to observe the frequency, type and degree of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect safety and efficacy information for evaluating the results of the clinical use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Amplatzer PFO Occluder

Trials testing the same drug.

Other recruiting trials for PFO - Patent Foramen Ovale

Currently open trials in the same condition.

Other Abbott Medical Devices trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04349995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing